Li D, Yang X, Zhang Z, Wang Z, Qi X, Ruan Y
PLoS One. 2016; 11(1):e0147422.
PMID: 26820145
PMC: 4731205.
DOI: 10.1371/journal.pone.0147422.
Bao B, Meng Z, Li N, Meng Z, Zhang L, Cao Y
Int J Mol Sci. 2013; 14(8):17193-203.
PMID: 23965980
PMC: 3759959.
DOI: 10.3390/ijms140817193.
Piret J, Desormeaux A, Cormier H, Lamontagne J, Gourde P, Juhasz J
Antimicrob Agents Chemother. 2000; 44(9):2263-70.
PMID: 10952566
PMC: 90056.
DOI: 10.1128/AAC.44.9.2263-2270.2000.
De Logu A, Williamson R, Rozenshteyn R, Ramiro-Ibanez F, Simpson C, Burton D
J Clin Microbiol. 1998; 36(11):3198-204.
PMID: 9774565
PMC: 105301.
DOI: 10.1128/JCM.36.11.3198-3204.1998.
Singh N, Yu V
Dig Dis Sci. 1998; 43(6):1190-2.
PMID: 9635606
DOI: 10.1023/a:1018839320383.
What clinicians need to know about antiviral drugs and viral resistance.
Hodinka R
Infect Dis Clin North Am. 1998; 11(4):945-67.
PMID: 9421709
PMC: 7173234.
DOI: 10.1016/s0891-5520(05)70399-8.
Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates.
Yao Y, Inoue Y, Kase T, Uchihori Y, Mori Y, Ohashi Y
Graefes Arch Clin Exp Ophthalmol. 1996; 234 Suppl 1:S126-32.
PMID: 8871163
DOI: 10.1007/BF02343061.
Acyclovir diphosphate dimyristoylglycerol: a phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus.
Hostetler K, Parker S, Sridhar C, Martin M, Li J, Stuhmiller L
Proc Natl Acad Sci U S A. 1993; 90(24):11835-9.
PMID: 8265634
PMC: 48079.
DOI: 10.1073/pnas.90.24.11835.
Continuous infusion of high-dose acyclovir for serious herpesvirus infections.
Fletcher C, Englund J, Bean B, Chinnock B, Brundage D, Balfour Jr H
Antimicrob Agents Chemother. 1989; 33(8):1375-8.
PMID: 2552909
PMC: 172658.
DOI: 10.1128/AAC.33.8.1375.
Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1.
ELLIS M, Waters R, Hill E, Lobe D, Selleseth D, Barry D
Antimicrob Agents Chemother. 1989; 33(3):304-10.
PMID: 2543278
PMC: 171483.
DOI: 10.1128/AAC.33.3.304.
Prophylaxis for genital herpes. Should it be used routinely?.
Mindel A
Drugs. 1991; 41(3):319-25.
PMID: 1711440
DOI: 10.2165/00003495-199141030-00001.
In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus.
Hill E, Hunter G, ELLIS M
Antimicrob Agents Chemother. 1991; 35(11):2322-8.
PMID: 1666496
PMC: 245379.
DOI: 10.1128/AAC.35.11.2322.
Resistance of herpesviruses to antiviral drugs.
Chatis P, Crumpacker C
Antimicrob Agents Chemother. 1992; 36(8):1589-95.
PMID: 1416838
PMC: 191999.
DOI: 10.1128/AAC.36.8.1589.
Comparative activity of various compounds against clinical strains of herpes simplex virus.
Andrei G, Snoeck R, Goubau P, Desmyter J, De Clercq E
Eur J Clin Microbiol Infect Dis. 1992; 11(2):143-51.
PMID: 1327785
DOI: 10.1007/BF01967066.
